abbott diabetics

HR Monitor:: Again you are an idiot and we doubt you actually work for this Company. Trolls like you must have a very low self esteem. Please CEASE AND DESIST.

 

As I said, I am a big fan of the Libre product. Know people who use it. Simple fact is Abbott does not have the guts to go farther with this....I know this as a fact. Abbott should have partnered with Google or Apple. Get some high end techies on these products. But they haven't and they won't.

Stupid.

Facts are facts. Libre will have a good run but in three years or less it will be an old technology and I doubt Abbott is spending the $50M a year or so required to keep up.....I have seen this before.

 

No, It's not lack of guts, as you say; its knowing when to be smart and not pour money into products with no future. Apple, Google, none of those high tech companies would ever return a phone call from Abbott. To leading edge companies and innovators, Abbott is your father's Oldsmobile. A relic. The facts are Libre may be an interesting product, and offer better diabetes management potential, but it costs several times BGM, which gets the job done for pennies on the Libre dollar. For that reason alone it is DOA. Add to that, Abbitt knows that the cost and time to bring Libre to market would never give the ROI they need, because the next gen high tech wearables will hit the market at the same time and blow LIbre out of the water.

 

Libre man here:

Libre is such a hit Google realised it needed to work with a name brand CGM company to catch up. So who did they pick? ADC? Medtronic? No, DexCom. Why? Because DecCom does not have the baggage of being a big pharma/device company. DexCom is young and their focus is narrow.

In a few years CGM will be a small disposible BLE patch that will cost no more than a buck or two a day. This is what can be done. It will be a wonder for the patients that need it.

 

To the poster who told everyone to cease and desist :

Don't worry about it. ADC will be retired to the Lost Civilisations thread in 2 years or so.

 

Senior DM here: You are way way off base. Those companies wouldn't touch anything from us. You must be a certified idiot to even suggest that. Or you are a mama's boy and never had a real job.

 

Miles White here: Get to work you leeches, I need a new Benz !!!!!!!

 

SR DM here: AMEN bro, these street reps better meet their numbers, I have alimony payments and my kids college tuition bills coming up. Thank God the new wife is an investment banker.

 

HAAAA...HAAAAA

idiot....

 

Libre boy is an idiot, proven every time he posts here. Sounds like a low level tech who thinks he knows how to save the company. He accepts as fact what he finds on a few obscure blogs, ME's vague pr statements, then extrapolates utterly fantastical guesses about Libre, all the while ignoring the many posts here by actual company employees who see the real facts. Best to not feed the troll.

 

You want to see an idiot? Go look in the mirror. To bad you were fired long ago, because the DM's posting here would all pay to get to PIP you out.

 

Google and DexCom will kick your butt.

 

Never worked there...what's a PIP? Pretty Insignificant Penis?

 

Your Brit...."realized".

 

ADC = Americas Dead Company

 

Your are very correct. Party WILL be over.....Libre has a mile or two left.

Google hooks up with DexCom to apply miniaturized electronics to diabetes monitoring
August 17, 2015 | By Nick Paul Taylor
Share


Tools

• Comment
• Print
• Contact Author
• Reprint

​

Google's headquarters--Courtesy of Google
Google ($GOOG) has made yet another move to apply its IT wizardry to life sciences. The latest deal, which became public one day after Google unveiled its life science-motivated restructuring, sees the tech giant hook up with DexCom ($DXCM) to marry its miniaturized electronics to diabetes sensors.

DexCom, a developer of continuous glucose monitoring systems, is contributing sensor technology to the alliance. By pairing its sensors with Google's miniaturized electronics, DexCom hopes to create wearable, disposable continuous glucose monitoring devices that are far smaller and cheaper than what is available today. Exactly how small and cheap the devices are remains to be seen, but Google has previously described its miniaturized electronics as "chips and sensors so small they look like bits of glitter."

The end goal for DexCom is to use this advanced technology to create a low-cost, cloud-connected, bandage-sized sensor that will supplant finger sticks as the standard of care. "This partnership has the potential to change the face of diabetes technology forever. Working together, we believe we can introduce products that will move us beyond our core Type 1 business to become the standard of care for all people living with diabetes," DexCom CEO Kevin Sayer said in a statement. DexCom is paying Google an undisclosed upfront fee and milestones for its contribution to realizing this vision.


[Webinar] Precision Medicine: Opportunities and Challenges for Clinical Trials
Date: Wednesday, September 2nd | 11:30am ET / 8:30am PT
In this webinar, Dr. Frank Smith will explore advances in precision medicine and how it is affecting clinical research. As a pediatric hematologist/oncologist, he will use his extensive clinical and research background as a backdrop for the discussion. Register Now!


Sign up for our FREE newsletter for more news like this sent to your inbox!
San Diego, CA-based DexCom will have full sales and distribution rights for products developed in the collaboration. The structure of the deal--which gives Google access to a life science market without having to handle regulatory and commercial tasks--is in keeping with its strategy to date. Last year, Google cofounder Sergey Brin said regulations made healthcare "a painful business to be in," a view that contributed to its decision to look for partners with experience of bringing medical devices to market. Novartis ($NVS) and now DexCom have signed up to handle that side of the process.

- read the release
- here's FierceMedicalDevices' take
- and FierceBiotech's restructuring news

 

Party's over:


R&D

Google hooks up with DexCom to apply miniaturized electronics to diabetes monitoring

August 17, 2015 | By Nick Paul Taylor

Share

var addthis_share = { url_transforms: { clean: true, add: { utm_campaign: 'AddThis', utm_medium: 'AddThis', utm_source: '{{code}}' } } }

Tools

• Comment
  
  
• Print
  
  
• Contact Author
  
  
• Reprint
  

Google's headquarters--Courtesy of Google

Google ($GOOG) has made yet another move to apply its IT wizardry to life sciences. The latest deal, which became public one day after Google unveiled its life science-motivated restructuring, sees the tech giant hook up with DexCom ($DXCM) to marry its miniaturized electronics to diabetes sensors.

DexCom, a developer of continuous glucose monitoring systems, is contributing sensor technology to the alliance. By pairing its sensors with Google's miniaturized electronics, DexCom hopes to create wearable, disposable continuous glucose monitoring devices that are far smaller and cheaper than what is available today. Exactly how small and cheap the devices are remains to be seen, but Google has previously described its miniaturized electronics as "chips and sensors so small they look like bits of glitter."

The end goal for DexCom is to use this advanced technology to create a low-cost, cloud-connected, bandage-sized sensor that will supplant finger sticks as the standard of care. "This partnership has the potential to change the face of diabetes technology forever. Working together, we believe we can introduce products that will move us beyond our core Type 1 business to become the standard of care for all people living with diabetes," DexCom CEO Kevin Sayer said in a statement. DexCom is paying Google an undisclosed upfront fee and milestones for its contribution to realizing this vision.

San Diego, CA-based DexCom will have full sales and distribution rights for products developed in the collaboration. The structure of the deal--which gives Google access to a life science market without having to handle regulatory and commercial tasks--is in keeping with its strategy to date. Last year, Google cofounder Sergey Brin said regulations made healthcare "a painful business to be in," a view that contributed to its decision to look for partners with experience of bringing medical devices to market. Novartis ($NVS) and now DexCom have signed up to handle that side of the process.

 

Pretty close. It's a special honor your manager gives you, and is the prelude to an early and long vacation, or an early retirement. The most surefire way to get one is to point out the emperor has no cloths.

 

And to tell him he has a "PIP" in his pants.

 

ADC is built tough just like a Ford truck! We're still standing in the ring having knocked out our competitors. ADC tough!